ALK and non-small cell lung carcinoma: A potential consideration in support of the use of definitive XRT for ALK-positive patients is Wang’s SINDAS trial, which demonstrated increased OS of metastatic NSCLC patients with EGFR mutation treated with aggressive radiotherapy in addition to EGFR TKI.27 Further studies of this issue are required.